Generate Biomedicines Inc. (GENB)
GENB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GENB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002100782 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $140.3M cash; operating cash flow -$60.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 129,096,666 (2026-10-29). | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $25.3M, sold $16K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.2M | -$87.7M | -$54.9M | $140.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $6.3M | -$67.3M | -$57.9M | $135.4M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $7.2M | -$61.4M | -$80.4M | $160.6M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q3 2026 2025-09-30 | $9.6M | -$53.6M | -$48.4M | $118.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2025-06-30 | $10.1M | -$52.4M | -$48.8M | $154.3M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2025-03-31 | $8.8M | -$41.7M | -$53.2M | $220.6M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 58 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.6% |
| 1 month | -1.5% |
| 3 months | -19.7% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -40.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| URGN | UroGen Pharma Ltd. | $28.10 | +7.33% | $1.4B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| AVLN | Avalyn Pharma Inc. | $29.76 | -1.72% | $1.3B |
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| LBRX | LB Pharmaceuticals Inc | $42.99 | -0.05% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier